Activity Overview
Physicians’ Education Resource®, LLC, (PER®) presents the 10th Annual Live Medical Crossfire®: Hematologic Malignancies—a 2-day Medical Crossfire designed to interactively explore the most controversial clinical issues in the field of hematologic malignancies through interactive panel discussions with renowned experts. This meeting contrasts the viewpoints of key opinion leaders across the country and the world regarding emerging clinical data and current standards of practice across liquid tumors. Through this valuable discussion, health care professionals participating in this conference can better treat a broad range of patients with hematologic malignancies, understand current controversies, and more confidently personalize clinical decisions.
At the start of each Medical Crossfire segment, renowned experts across the field of hematology—from leukemias and lymphomas to myeloma—present a brief evidence-based assessment of current standards of practice and the most important recent clinical trials to set the stage for each expert crossfire session. Sessions conclude with crossfire questions from the live audience.
This Medical Crossfire: Hematologic Malignancies program offers hematologists/oncologists who are involved in the care of patients with hematologic malignancies the opportunity to build their base of clinical knowledge on new and emerging agents, maintain awareness of controversies in the field, and apply the best practices for the care of their patients to optimize outcomes.
This educational activity is an archive of the live conference held on July 11-12, 2026.
Target Audience
This educational activity is directed toward hematologists, medical oncologists, and fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the efficacy and safety of approved and emerging therapies based on current clinical trial data
- Select appropriate initial therapy using clinical evidence, guidelines, and patient- and disease-specific factors (including biomarkers)
- Develop longitudinal treatment strategies that incorporate sequencing across lines of therapy, prior treatment exposure, and anticipated next-line options
- Identify, monitor, and manage treatment-related adverse events across therapeutic classes
- Integrate multidisciplinary care strategies to further optimize the treatment of hematologic malignancies
Barbara Pro, MD
Professor of Medicine, Division of Hematology and Oncology
Columbia University Vagelos College of Physicians and Surgeons
Clinical Director, Lymphoma Program
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Irving Medical Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Secura Bio; Grant/Research Funding: ONO Pharmaceutical, SciTech
Saad Z. Usmani, MD, MBA, FACP, FASCO
Professor
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Bristol Myers Squibb/Celgene, Gilead, Gracell Biotechnologies, GSK, Janssen; Grant/Research Funding: AbbVie, Bristol Myers Squibb/Celgene, Genentech, Gilead, GSK, Janssen, Kite/Arcellx, Oricell Therapeutics, Pfizer, Regeneron, Sanofi
Amer Zeidan, MD, MBBS
Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale School of Medicine
Yale Cancer Center
Smilow Cancer Hospital
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Akeso Biopharma, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone BioPharma, Daiichi Sankyo, Dr Reddy's, Epizyme, Faron, FibroGen, Genentech, Geron, Gilead, GlycoMimetics, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrödinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis; Grant/Research Funding: AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
